J-Code for Glaukos’ iDose TR Becomes Active

Glaukos announced that the CMS Healthcare Common Procedure Coding System’s J-code—J7355—for the company’s iDose TR is effective. The J-code provides patient access and streamlines the coverage and payment process as Glaukos advances its commercial launch of the treatment.

According to Glaukos, the new J-code simplifies and ensures consistent coverage, facilitating broader access to iDose TR across the US. Additionally, providers will benefit from a more dependable payment process, facilitating smoother integration into patient care routines.

In April, Glaukos announced that CMS assigned the unique, permanent J-code for iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of IOP in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG).

FDA approval of iDose TR was announced in December 2023.

Glaukos’ iDose TR is a long-duration, intracameral procedural pharmaceutical therapy. The therapy is designed to continuously deliver 24/7 therapeutic levels of the company’s formulation of travoprost inside the eye for extended periods of time. It is intended to deliver therapies for OHT and OAG that address noncompliance and reduce the treatment burden for patients, stated the company.